$PHIO
Phio Pharmaceuticals Corp

2018 Q1 Form 10-K Financial Statement

#000119312518096053 Filed on March 26, 2018

View on sec.gov

Income Statement

Concept 2018 Q1 2017 2016 Q4
Revenue $23.00K $15.00K $0.00
YoY Change -21.05%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $900.0K $4.010M $1.030M
YoY Change -19.64% 10.77% 14.44%
% of Gross Profit
Research & Development $1.361M $5.370M $1.310M
YoY Change 1.04% -0.83% -23.84%
% of Gross Profit
Depreciation & Amortization $20.00K $70.00K $10.00K
YoY Change 81.82% 32.08% -50.0%
% of Gross Profit
Operating Expenses $2.262M $14.08M $2.340M
YoY Change -68.06% 55.82% -10.69%
Operating Profit -$2.239M -$14.06M
YoY Change -68.38% 55.98%
Interest Expense -$1.000K $0.00
YoY Change -106.67% -100.0%
% of Operating Profit
Other Income/Expense, Net $0.00 -$11.00K $0.00
YoY Change -152.38%
Pretax Income -$2.239M -$14.07M -$2.340M
YoY Change -68.38% 56.47% -10.69%
Income Tax $0.00 -$1.621M $0.00
% Of Pretax Income
Net Earnings -$2.239M -$12.45M -$2.340M
YoY Change -58.99% 38.45% -10.69%
Net Earnings / Revenue -9734.78% -83013.33%
Basic Earnings Per Share
Diluted Earnings Per Share -$44.80M -$311.3M -$234.0M
COMMON SHARES
Basic Shares Outstanding 2.595M shares 6.600M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q1 2017 2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.610M $3.580M $12.91M
YoY Change -74.44% -72.27% 21.56%
Cash & Equivalents $2.606M $3.580M $12.91M
Short-Term Investments
Other Short-Term Assets $260.0K $250.0K $200.0K
YoY Change 44.44% 25.0% -44.44%
Inventory
Prepaid Expenses $150.0K
Receivables
Other Receivables
Total Short-Term Assets $2.862M $3.830M $13.11M
YoY Change -72.43% -70.79% 19.38%
LONG-TERM ASSETS
Property, Plant & Equipment $228.0K $250.0K $114.0K
YoY Change 117.14% 127.27% -30.06%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $20.00K $27.00K
YoY Change -33.33% 50.0%
Total Long-Term Assets $228.0K $270.0K $291.0K
YoY Change 72.73% -6.9% 60.77%
TOTAL ASSETS
Total Short-Term Assets $2.862M $3.830M $13.11M
Total Long-Term Assets $228.0K $270.0K $291.0K
Total Assets $3.090M $4.100M $13.40M
YoY Change -70.61% -69.4% 20.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $521.0K $510.0K $917.0K
YoY Change -22.47% -44.57% -21.15%
Accrued Expenses $2.002M $1.750M $1.625M
YoY Change 25.67% 7.36% 46.93%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.523M $2.270M $2.542M
YoY Change 11.39% -10.63% 12.03%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.523M $2.270M $2.542M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $2.520M $2.270M $2.540M
YoY Change 11.01% -10.63% 11.89%
SHAREHOLDERS EQUITY
Retained Earnings -$80.79M -$66.10M
YoY Change 12.9% 15.75%
Common Stock $0.00 $0.00
YoY Change -100.0% -100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $567.0K $1.830M $10.86M
YoY Change
Total Liabilities & Shareholders Equity $3.090M $4.100M $13.40M
YoY Change -70.61% -69.4% 20.06%

Cashflow Statement

Concept 2018 Q1 2017 2016 Q4
OPERATING ACTIVITIES
Net Income -$2.239M -$12.45M -$2.340M
YoY Change -58.99% 38.45% -10.69%
Depreciation, Depletion And Amortization $20.00K $70.00K $10.00K
YoY Change 81.82% 32.08% -50.0%
Cash From Operating Activities -$1.910M -$9.510M -$1.370M
YoY Change -31.79% 22.55% -13.29%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $203.0K $0.00
YoY Change -100.0% 4975.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $100.0K $1.850M
YoY Change -100.0% -98.13% -26.0%
Cash From Investing Activities $0.00 -$100.0K $1.850M
YoY Change -100.0% -101.87% -25.4%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $932.0K $10.05M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 930.0K 290.0K 10.05M
YoY Change -97.16% 5189.47%
NET CHANGE
Cash From Operating Activities -1.910M -9.510M -1.370M
Cash From Investing Activities 0.000 -100.0K 1.850M
Cash From Financing Activities 930.0K 290.0K 10.05M
Net Change In Cash -975.0K -9.325M 10.53M
YoY Change -63.9% -219.72% 866.06%
FREE CASH FLOW
Cash From Operating Activities -$1.910M -$9.510M -$1.370M
Capital Expenditures $0.00 $203.0K $0.00
Free Cash Flow -$1.910M -$9.713M -$1.370M
YoY Change -31.83% 25.1% -12.18%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
2594962 shares
CY2017Q2 dei Entity Public Float
EntityPublicFloat
13542277
CY2015Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5167000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
8890000
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1625000
CY2016Q4 us-gaap Assets Current
AssetsCurrent
13106000
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
104000
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
831000
CY2016Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
73429000
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
917000
CY2016Q4 us-gaap Assets
Assets
13397000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12906000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12956000
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1300318 shares
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2429993 shares
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
0
CY2016Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
5385000
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
25528000
CY2016Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
17245000
CY2016Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
745000
CY2016Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
262000
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
25528000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1891000
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
745000
CY2016Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13397000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2542000
CY2016Q4 us-gaap Notes And Loans Receivable Net Noncurrent
NotesAndLoansReceivableNetNoncurrent
150000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
10000
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
27000
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
150000
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
114000
CY2016Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
50000
CY2016Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
50000
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-66099000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
37444 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
272.90
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
10855000
CY2016Q4 rxii Clinical Development Expenses Current
ClinicalDevelopmentExpensesCurrent
490000
CY2016Q4 rxii Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
276000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1754000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
3832000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
167000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
900000
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
80384000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
511000
CY2017Q4 us-gaap Assets
Assets
4098000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3581000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3631000
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1300318 shares
CY2017Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1408000 shares
CY2017Q4 us-gaap Contractual Obligation Due In Fourth Year
ContractualObligationDueInFourthYear
165000
CY2017Q4 us-gaap Contractual Obligation Due In Second Year
ContractualObligationDueInSecondYear
165000
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2429993 shares
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
0
CY2017Q4 us-gaap Contractual Obligation
ContractualObligation
1495000
CY2017Q4 us-gaap Contractual Obligation Due In Third Year
ContractualObligationDueInThirdYear
165000
CY2017Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
3393000
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
20907000
CY2017Q4 us-gaap Contractual Obligation Due In Fifth Year
ContractualObligationDueInFifthYear
100000
CY2017Q4 us-gaap Contractual Obligation Due In Next Twelve Months
ContractualObligationDueInNextTwelveMonths
200000
CY2017Q4 us-gaap Contractual Obligation Due After Fifth Year
ContractualObligationDueAfterFifthYear
700000
CY2017Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
14681000
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
1322000
CY2017Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
175000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
20907000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1336000
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
735000
CY2017Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
157000
CY2017Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4098000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2265000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
8000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
150000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
30000
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
18000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
120000
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
201000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
248000
CY2017Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
50000
CY2017Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
50000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-78551000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
125000 shares
CY2017Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
74824 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
33913 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
275.30
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
50156 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
192.30
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
1833000
CY2017Q4 rxii Clinical Development Expenses Current
ClinicalDevelopmentExpensesCurrent
261000
CY2017Q4 rxii Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
583000
CY2017Q1 us-gaap Stock Issued During Period Shares Purchase Of Assets
StockIssuedDuringPeriodSharesPurchaseOfAssets
275036 shares
CY2017Q1 rxii Holdback Percentage
HoldbackPercentage
0.03 pure
CY2017Q1 rxii Additional Number Common Stock To Be Issued Upon Milestone Achievement Percentage
AdditionalNumberCommonStockToBeIssuedUponMilestoneAchievementPercentage
0.13 pure
CY2017Q1 rxii Shares Of Common Stock Available For Issuance Upon Milestone Achievement
SharesOfCommonStockAvailableForIssuanceUponMilestoneAchievement
251909 shares
CY2017Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y8M12D
CY2017 dei Amendment Flag
AmendmentFlag
false
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1458156 shares
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
314000
CY2017 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <i>Concentrations of Credit Risk</i></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash. The Company maintains cash balances in several accounts with one bank, which at times are in excess of federally insured limits. The Company has established guidelines related to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. The Company&#x2019;s investments are maintained in accordance with the Company&#x2019;s investment policy, which defines allowable investments, specifies credit quality standards and limits the exposure of any single issuer.</p> </div>
CY2017 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
100000
CY2017 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-9325000
CY2017 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2017 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2017 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0
CY2017 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2017 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
2945000
CY2017 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-1621000
CY2017 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-1568000
CY2017 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
70000
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.52
CY2017 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
CY2017 dei Document Type
DocumentType
10-K
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.115 pure
CY2017 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2017 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.315 pure
CY2017 dei Document Period End Date
DocumentPeriodEndDate
2017-12-31
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.065 pure
CY2017 dei Entity Registrant Name
EntityRegistrantName
RXi Pharmaceuticals Corp
CY2017 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2017 dei Entity Central Index Key
EntityCentralIndexKey
0001533040
CY2017 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.625 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.005 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.025 pure
CY2017 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2017 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2017 us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
2824000
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4011000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-14073000
CY2017 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
129000
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1621000
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-608000
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
51000
CY2017 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-1000
CY2017 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2019-03-31
CY2017 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
115000
CY2017 us-gaap Maturities Of Time Deposits Description
MaturitiesOfTimeDepositsDescription
Three months or less
CY2017 us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b>1. Nature of Operations</b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> RXi Pharmaceuticals Corporation is a biotechnology company focused on discovering and developing immuno-oncology therapeutics to treat cancer based on its self-delivering RNAi (&#x201C;<b><font style="white-space:nowrap">sd-rxRNA</font></b><b><sup style="font-size:85%; vertical-align:top">&#xAE;</sup></b>&#x201D;) platform. The Company&#x2019;s <font style="white-space:nowrap">sd-rxRNA</font> compounds do not require a delivery vehicle to penetrate the cell and are designed to &#x201C;silence,&#x201D; or down-regulate, the expression of a specific gene that may be over-expressed in a disease condition. This provides RXi with a distinct advantage in adoptive cell therapy, the Company&#x2019;s initial focus and approach to immuno-oncology.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> Prior to RXi&#x2019;s acquisition of MirImmune Inc. (&#x201C;<b>MirImmune</b>&#x201D;) in January 2017, the Company&#x2019;s principal activities consisted of the preclinical and clinical development of the Company&#x2019;s <font style="white-space:nowrap">sd-rxRNA</font> compounds and topical immunotherapy agent in the areas of dermatology and ophthalmology. With the acquisition of MirImmune, the Company completed a thorough review of its business operations, development programs and financial resources and made a strategic decision to focus solely on immuno-oncology to accelerate growth and in turn support a return on investment for its stockholders. As a result, the Company will seek to monetize its valuable dermatology and ophthalmology franchises through out-licensing or partnerships, thereby enabling a streamlined focus of the Company&#x2019;s resources on the development of its immuno-oncology program, with a focus on adoptive cell transfer.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> On January&#xA0;3, 2018, the Board of Directors of the Company approved a <font style="white-space:nowrap"><font style="white-space:nowrap">1-for-10</font></font> reverse stock split of the Company&#x2019;s outstanding common stock, which was effected on January&#xA0;8, 2018. All share and per share amounts in the financial statements have been retroactively adjusted for all periods presented to give effect to the reverse stock split, including reclassifying an amount equal to the reduction in par value to additional <font style="white-space:nowrap">paid-in</font> capital.</p> </div>
CY2017 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-103000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-9514000
CY2017 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12452000
CY2017 us-gaap Operating Expenses
OperatingExpenses
14077000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
292000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-12452000
CY2017 us-gaap Noncash Or Part Noncash Acquisition Payables Assumed1
NoncashOrPartNoncashAcquisitionPayablesAssumed1
5000
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-14062000
CY2017 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-11000
CY2017 us-gaap Notes Reduction
NotesReduction
150000
CY2017 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-10000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
203000
CY2017 us-gaap Payments For Rent
PaymentsForRent
9500
CY2017 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
2000
CY2017 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
290000
CY2017 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
4696000
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5370000
CY2017 us-gaap Revenues
Revenues
15000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
314000
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.2301 pure
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
20326 shares
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y7M13D
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
39.50
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000 pure
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.8299 pure
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0173 pure
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y6M10D
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.90
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.90
CY2017 us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
0 shares
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.8465 pure
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
22000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0249 pure
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
33038 shares
CY2017 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2017 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2000
CY2017 us-gaap Stock Issued During Period Shares Purchase Of Assets
StockIssuedDuringPeriodSharesPurchaseOfAssets
275036 shares
CY2017 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
290000
CY2017 us-gaap Stock Issued During Period Value Purchase Of Assets
StockIssuedDuringPeriodValuePurchaseOfAssets
2824000
CY2017 dei Trading Symbol
TradingSymbol
RXII
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2257754 shares
CY2017 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
2998000
CY2017 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <i>Uses of Estimates in Preparation of Financial Statements</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from these estimates.</p> </div>
CY2017 rxii Value Of Nonmarketable Equity Securities Recognized As Revenue
ValueOfNonmarketableEquitySecuritiesRecognizedAsRevenue
-9000
CY2017 rxii Deferred Income Tax Expense Benefit Gross
DeferredIncomeTaxExpenseBenefitGross
1377000
CY2017 rxii Tax Credit Carryforward Research Expiration Period
TaxCreditCarryforwardResearchExpirationPeriod
2037
CY2017 rxii Operating Loss Carryforwards Expiration Year
OperatingLossCarryforwardsExpirationYear
2037
CY2017 rxii Tax Reform Impact Deferred Tax Assets
TaxReformImpactDeferredTaxAssets
8800000
CY2017 rxii Tax Cuts And Jobs Act Of2017 Change In Tax Rate Deferred Tax Assets Increase Decrease In Valuation Allowance
TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxAssetsIncreaseDecreaseInValuationAllowance
-4621000
CY2016 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2082934 shares
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
756000
CY2016 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
7789000
CY2016 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2016 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2016 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0
CY2016 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-2892000
CY2016 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-741000
CY2016 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
53000
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-16.41
CY2016 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.404 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.046 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.017 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.035 pure
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3619000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8994000
CY2016 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
519000
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-246000
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-161000
CY2016 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
15000
CY2016 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
117000
CY2016 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
5346000
CY2016 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-7760000
CY2016 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11069000
CY2016 us-gaap Operating Expenses
OperatingExpenses
9034000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
10203000
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-8994000
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-9015000
CY2016 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
21000
CY2016 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
6000
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4000
CY2016 us-gaap Payments To Acquire Notes Receivable
PaymentsToAcquireNotesReceivable
150000
CY2016 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
2000000
CY2016 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
2075000
CY2016 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
7500000
CY2016 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
10203000
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5415000
CY2016 us-gaap Revenues
Revenues
19000
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
756000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.1688 pure
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000 pure
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7942 pure
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0118 pure
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
21.50
CY2016 us-gaap Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
7064000
CY2016 us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
0 shares
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.8912 pure
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0202 pure
CY2016 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
152000
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
674608 shares
CY2016 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-3633000
CY2016 rxii Value Of Nonmarketable Equity Securities Recognized As Revenue
ValueOfNonmarketableEquitySecuritiesRecognizedAsRevenue
9000
CY2016 rxii Issuance Of Common Stock And Warrants In Connection With Public Offering Net Of Offering Costs Value
IssuanceOfCommonStockAndWarrantsInConnectionWithPublicOfferingNetOfOfferingCostsValue
2987000
CY2016 rxii Deferred Income Tax Expense Benefit Gross
DeferredIncomeTaxExpenseBenefitGross
-3633000
CY2016 rxii Tax Cuts And Jobs Act Of2017 Change In Tax Rate Deferred Tax Assets Increase Decrease In Valuation Allowance
TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxAssetsIncreaseDecreaseInValuationAllowance
3633000

Files In Submission

Name View Source Status
0001193125-18-096053-index-headers.html Edgar Link pending
0001193125-18-096053-index.html Edgar Link pending
0001193125-18-096053.txt Edgar Link pending
0001193125-18-096053-xbrl.zip Edgar Link pending
d488401d10k.htm Edgar Link pending
d488401dex231.htm Edgar Link pending
d488401dex311.htm Edgar Link pending
d488401dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g488401g0321125051478.jpg Edgar Link pending
g488401g0321125051712.jpg Edgar Link pending
g488401g0321125051899.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rxii-20171231.xml Edgar Link completed
rxii-20171231.xsd Edgar Link pending
rxii-20171231_cal.xml Edgar Link unprocessable
rxii-20171231_def.xml Edgar Link unprocessable
rxii-20171231_lab.xml Edgar Link unprocessable
rxii-20171231_pre.xml Edgar Link unprocessable
Show.js Edgar Link pending